CareDx (CDNA)
NASDAQ:CDNA
Want to see CDNA full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.24Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong top-line growth, substantial margin and EBITDA improvement, raised full‑year guidance, a strategic simplification via a Lab Products divestiture (expected ~$160M net proceeds), and a targeted acquisition (Navaris) that expands addressable markets with strong clinical evidence and favorable reimbursement. Challenges include modest profitability and declining trends in the Lab Products segment prior to divestiture, revenue recognition timing noise, reimbursement/LCD risk (~$7.5M modeled headwind), elevated operating expenses and uncertainty in transplant procedure volumes, and integration/scale risks for Navaris and the product carve-out. On balance, the positive growth, improved profitability, cash position, and strategic actions outweigh the execution and timing risks discussed on the call.Company Guidance
Strong Q1 Revenue and Volume Growth
Total revenue increased 39% year-over-year to $118.0M in Q1 2026; testing volume rose 17% to 54,900 tests.
Testing Services and Patient/Digital Solutions Expansion
Testing services revenue grew 48% to $91M (average reported $16.60 per test); patient and digital solutions revenue increased 33% to $16M.
Improved Profitability Metrics
Non-GAAP gross margin rose to 73%; adjusted EBITDA was $19M, up over 300% year-over-year; GAAP net income was $3M and GAAP EPS $0.05.
Cash Strength and Collections
Cash collections increased 52% to $121M; ended the quarter with $198M in cash and cash equivalents and no debt; cash flow from operations was $4M for the quarter and $72M over the last four quarters.
Raised Full-Year 2026 Guidance
Revenue guidance raised to $447M–$465M (midpoint $456M, ~20% YoY growth); adjusted EBITDA guidance $43M–$57M (midpoint $50M, ~58% YoY); testing volume guide 224k–229k tests (midpoint 226.5k, ~13% YoY).
Portfolio Optimization — Lab Products Divestiture
Announced definitive agreement to divest Lab Products for $170M upfront (expected net ~$160M after estimated $10M transaction expenses), simplifying focus on testing services and digital/patient solutions; core businesses delivered 48% and 33% revenue growth, respectively, in Q1.
Strategic Acquisition — Navaris
Announced acquisition of Navaris (tumor‑naive TTMV MRD platform): Navaris has performed >130,000 tests, ~2,000 active ordering physicians, ~100 employees, Medicare coverage for ~100M lives, ADLT designation with $1,800 reimbursement/test; estimated 2025 revenue $34M with expected 30%–40%+ growth over the next three years.
Strong Clinical Evidence and Thought Leadership
Navaris supported by 56 peer-reviewed publications; a real-world multicenter study (n=543) showed NPV 98% and PPV 95% for post-treatment MRD surveillance, with median lead time for recurrence detection ~4 months; CareDx data featured in >50 abstracts at ISHLT including 16 oral presentations.
Pipeline and Product Progress
Advancements across key programs: Alaheme cell therapy program data (ACROBAT) presented; AlloSure liver progressing in MAPLE trial with follow-up data collection; HistoMap kidney moving toward launch with a second clinical validation manuscript submitted and CLIA readiness progressing.
Workflow and Integration Momentum
Targeting ~50% of testing volume through Epic-integrated sites by year-end; nine centers live and 16 integrations underway; field support team exceeds 120 members to support center workflows and patient blood collection.
CDNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CDNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 28, 2026 | $21.91 | $20.80 | -5.07% |
Feb 24, 2026 | $19.25 | $18.46 | -4.10% |
Nov 04, 2025 | $14.52 | $16.53 | +13.84% |
Aug 06, 2025 | $13.10 | $12.07 | -7.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CareDx (CDNA) report earnings?
CareDx (CDNA) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is CareDx (CDNA) earnings time?
CareDx (CDNA) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDNA EPS forecast?
CDNA EPS forecast for the fiscal quarter 2026 (Q2) is 0.24.
